Where does Vertex Pharmaceuticals Incorporated rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Vertex Pharmaceuticals Incorporated ranks #1,267 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Vertex Pharmaceuticals Incorporated hold?

Vertex Pharmaceuticals Incorporated holds 334 US utility patents granted between 2015 and 2025, spanning 24 technology areas.

What is Vertex Pharmaceuticals Incorporated's Innovation Score?

Vertex Pharmaceuticals Incorporated has an Innovation Score of 57.9 out of 100 (top 5% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Vertex Pharmaceuticals Incorporated focus on?

Vertex Pharmaceuticals Incorporated's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 270 patents, ranking #45 of 6,058 assignees active in that subclass. Grants appear in 24 CPC subclasses total.

Is Vertex Pharmaceuticals Incorporated's patent grant rate increasing or decreasing?

Vertex Pharmaceuticals Incorporated's recent grant velocity is -21% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Vertex Pharmaceuticals Incorporated's patents?

Vertex Pharmaceuticals Incorporated's patents average 23.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Vertex Pharmaceuticals Incorporated patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Vertex Pharmaceuticals Incorporated

USPTO PatentsView assignee record - 334 granted patents across 24 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Vertex ranks #1,267 of 49,997 tracked US assignees by granted-patent volume, with 334 patents across 24 technology areas.

#1,267
of 49,997 US assignees by volume: Top 5%
by Innovation Score (57.9/100): 23.5
avg claims per patent: -21%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1267 · US Corporation #1,267 · 334 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 334 grants
TOP-DECILE #1,267/49,997
PHOTO-FINISH K2M
CPC-FOCUS A61P · 24 areas
INNOV-PAR 57.9/100
CLAIMS-DENSE 23.5 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -21% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: K2M, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Vertex’s 57.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 20.1 pts (35%) Velocity 6.3 pts (11%) Breadth 17.3 pts (30%) Claim depth 14.1 pts (24%)

Qualcomm Incorporated · highest

85
IPG Photonics · near

58
Materion · near

58
Sensata · near

58
Technische Universit… · near

58
Vertex Pharmaceutica… · this assignee

58
3D Lighting… · lowest

7

What this shows Vertex's Innovation Score is 57.9/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Vertex?

Each dot is one of Vertex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Vertex’s own 23.5 claims/patent is ABOVE the 17.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Vertex vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Vertex's grants concentrate

Vertex Pharmaceuticals Incorporated is a focused PatentsView assignee: 24 CPC subclasses with 80.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (57 grants) versus a trough of 23 in 2022. By volume, Vertex sits between Cummins Emission Solutions Inc. and Cartier International AG.

Vertex's three-year grant acceleration

From 2019–2021 to 2022–2024, Vertex Pharmaceuticals Incorporated moved from 81 to 77 grants (0.95x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,316. See the growth leaderboard.

Cummins Emission…

335
Sophos

335
K2M

334
Unimicron Technol…

334
Vertex Pharmaceut… ◀

334
Conduent Business…

333
Mentor Graphics

333
Toyo Seikan

333
Cartier Internati…

332

What this shows Vertex holds 334 patents at rank #1,267, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Vertex

By rank, the assignees closest to #1,267 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Vertex's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Vertex, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Vertex ranks #45 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (58 here).

Materion Corporation 58 Sensata Technologies, Inc. 58 IPG Photonics Corporation 58 Technische Universität Wien 58

Similar claim depth

Nearest assignees by average claims per patent (23.5 here).

Omnitracs, LLC 23.5 avg Cochlear Limited 23.5 avg Terrapower, LLC 23.5 avg Graphic Packaging International, LLC 23.5 avg

Vertex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Vertex Pharmaceuticals Incorporated patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	57	17.1%
2016	34	10.2%
2017	28	8.4%
2018	26	7.8%
2019	24	7.2%
2020	33	9.9%
2021	24	7.2%
2022	23	6.9%
2023	23	6.9%
2024	31	9.3%
2025partial year	31	9.3%

Which technologies does Vertex Pharmaceuticals Incorporated patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 270

C07D - Heterocyclic Compounds 261

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 218

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 55

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 39

C07C - Acyclic OR Carbocyclic Compounds 31

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 29

C07K - Peptides 23

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 21

Y02A - Technologies FOR Adaptation TO Climate Change 16

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 13

C12Y - Enzymes 11

Y10T - Technical Subjects Covered BY Former US Classification 9

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 8

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 7

Top 15 of 24 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Vertex Pharmaceuticals Incorporated's patent record in context - here's where to go next.

Vertex Pharmaceuticals Incorporated's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,267 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Vertex Pharmaceuticals Incorporated against Cummins Emission Solutions Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 57.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.